Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Sep;39(9):2042–2047. doi: 10.1128/aac.39.9.2042

Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants.

M A Amantea 1, R A Bowden 1, A Forrest 1, P K Working 1, M S Newman 1, R D Mamelok 1
PMCID: PMC162878  PMID: 8540713

Abstract

The purpose of this study was to evaluate the pharmacokinetics of amphotericin B colloidal dispersion and its effect on creatinine clearance in bone marrow transplant patients with systemic fungal infections. Seventy-five patients (42 females and 33 males) with a median age of 34.5 years and a median weight of 70.0 kg were enrolled in the study. Patients received 1 of 15 dose levels (range, 0.5 to 8.0 mg/kg of body weight) daily for a mean duration of 28 days and a mean cumulative dose amount of 8 g. Plasma samples for amphotericin B determination (median number, 4; range, 2 to 30) and daily serum creatinine values were obtained for each patient. Iterative two-stage analysis, one of several approaches to population pharmacokinetic and pharmacodynamic modelling, was employed for the pharmacokinetic analysis. The plasma data were available for 51 of 75 patients and were best described by a two-compartment model. Both plasma clearance and volume of distribution increased with escalating doses; the overall average terminal elimination half-life was 29 h. Of the covariates studied, only body weight and dose size were significant. Serum creatinine values over the duration of therapy were available for 59 of 75 patients. Overall, there was no net change in renal function over the duration of therapy; 12 patients had > 30% increases in creatinine clearance, whereas 13 had > 30% decreases. No measure of amphotericin B colloidal dispersion exposure, demographic values, or concomitant treatment with other medications was related to changes in the creatinine clearance.

Full Text

The Full Text of this article is available as a PDF (207.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkinson A. J., Jr, Bennett J. E. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother. 1978 Feb;13(2):271–276. doi: 10.1128/aac.13.2.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barwicz J., Gareau R., Audet A., Morisset A., Villiard J., Gruda I. Inhibition of the interaction between lipoproteins and amphotericin B by some delivery systems. Biochem Biophys Res Commun. 1991 Dec 16;181(2):722–728. doi: 10.1016/0006-291x(91)91250-g. [DOI] [PubMed] [Google Scholar]
  3. Chiou W. L., Hsu F. H. Pharmacokinetics of creatinine in man and its implications in the monitoring of renal function and in dosage regimen modifications in patients with renal insufficiency. J Clin Pharmacol. 1975 May-Jun;15(5-6):427–434. doi: 10.1002/j.1552-4604.1975.tb02364.x. [DOI] [PubMed] [Google Scholar]
  4. D'Argenio D. Z., Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed. 1979 Mar;9(2):115–134. doi: 10.1016/0010-468x(79)90025-4. [DOI] [PubMed] [Google Scholar]
  5. Fielding R. M., Singer A. W., Wang L. H., Babbar S., Guo L. S. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother. 1992 Feb;36(2):299–307. doi: 10.1128/aac.36.2.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fielding R. M., Smith P. C., Wang L. H., Porter J., Guo L. S. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother. 1991 Jun;35(6):1208–1213. doi: 10.1128/aac.35.6.1208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fields B. T., Jr, Bates J. H., Abernathy R. S. Effect of rapid intravenous infusion on serum concentrations of amphotericin B. Appl Microbiol. 1971 Oct;22(4):615–617. doi: 10.1128/am.22.4.615-617.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Forrest A., Ballow C. H., Nix D. E., Birmingham M. C., Schentag J. J. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother. 1993 May;37(5):1065–1072. doi: 10.1128/aac.37.5.1065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hammond S. M. Biological activity of polyene antibiotics. Prog Med Chem. 1977;14:105–179. doi: 10.1016/s0079-6468(08)70148-6. [DOI] [PubMed] [Google Scholar]
  10. Hay R. J. Overview of the treatment of disseminated fungal infections. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):17–25. doi: 10.1093/jac/28.suppl_b.17. [DOI] [PubMed] [Google Scholar]
  11. Kan V. L., Bennett J. E., Amantea M. A., Smolskis M. C., McManus E., Grasela D. M., Sherman J. W. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J Infect Dis. 1991 Aug;164(2):418–421. doi: 10.1093/infdis/164.2.418. [DOI] [PubMed] [Google Scholar]
  12. Kirsh R., Goldstein R., Tarloff J., Parris D., Hook J., Hanna N., Bugelski P., Poste G. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis. 1988 Nov;158(5):1065–1070. doi: 10.1093/infdis/158.5.1065. [DOI] [PubMed] [Google Scholar]
  13. Lopez-Berestein G., Bodey G. P., Frankel L. S., Mehta K. Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol. 1987 Feb;5(2):310–317. doi: 10.1200/JCO.1987.5.2.310. [DOI] [PubMed] [Google Scholar]
  14. Lopez-Berestein G., Fainstein V., Hopfer R., Mehta K., Sullivan M. P., Keating M., Rosenblum M. G., Mehta R., Luna M., Hersh E. M. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985 Apr;151(4):704–710. doi: 10.1093/infdis/151.4.704. [DOI] [PubMed] [Google Scholar]
  15. Meyers J. D. Fungal infections in bone marrow transplant patients. Semin Oncol. 1990 Jun;17(3 Suppl 6):10–13. [PubMed] [Google Scholar]
  16. Peterson L. R., Kelty R. H., Hall W. H., Votava H. J. Therapy of Candida peritonitis: penetration of amphotericin B into peritoneal fluid. Postgrad Med J. 1978 May;54(631):340–342. doi: 10.1136/pgmj.54.631.340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sanders S. W., Buchi K. N., Goddard M. S., Lang J. K., Tolman K. G. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob Agents Chemother. 1991 Jun;35(6):1029–1034. doi: 10.1128/aac.35.6.1029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sarosi G. A. Amphotericin B. Still the 'gold standard' for antifungal therapy. Postgrad Med. 1990 Jul;88(1):151-2, 155-61, 165-6. doi: 10.1080/00325481.1990.11716368. [DOI] [PubMed] [Google Scholar]
  19. Sheiner L. B. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev. 1984;15(1-2):153–171. doi: 10.3109/03602538409015063. [DOI] [PubMed] [Google Scholar]
  20. Shirkhoda A., Lopez-Berestein G., Holbert J. M., Luna M. A. Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B. Radiology. 1986 May;159(2):349–353. doi: 10.1148/radiology.159.2.3961167. [DOI] [PubMed] [Google Scholar]
  21. Shulman H., Striker G., Deeg H. J., Kennedy M., Storb R., Thomas E. D. Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury. N Engl J Med. 1981 Dec 3;305(23):1392–1395. doi: 10.1056/NEJM198112033052306. [DOI] [PubMed] [Google Scholar]
  22. Steimer J. L., Mallet A., Golmard J. L., Boisvieux J. F. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev. 1984;15(1-2):265–292. doi: 10.3109/03602538409015066. [DOI] [PubMed] [Google Scholar]
  23. Walsh T. J., Pizzo A. Treatment of systemic fungal infections: recent progress and current problems. Eur J Clin Microbiol Infect Dis. 1988 Aug;7(4):460–475. doi: 10.1007/BF01962595. [DOI] [PubMed] [Google Scholar]
  24. Wasan K. M., Brazeau G. A., Keyhani A., Hayman A. C., Lopez-Berestein G. Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob Agents Chemother. 1993 Feb;37(2):246–250. doi: 10.1128/aac.37.2.246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Wheeler L. A., Sheiner L. B. Clinical estimation of creatinine clearance. Am J Clin Pathol. 1979 Jul;72(1):27–32. doi: 10.1093/ajcp/72.1.27. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES